Caveolin-1 in oral squamous cell carcinoma microenvironment: an overview

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9487-9495

  Routray, Samapika ^a  

^a SIKSHA O ANUSANDHAN DEEMED TO BE UNIVERSITY   (India)

Author keywords

Cav 1; HNSCC; Hypoxia; OSCC; Oxidative stress; Tumor microenvironment

Indexed keywords

CAV1 PROTEIN, HUMAN; CAVEOLIN 1;

HUMAN; METABOLISM; MOUTH TUMOR; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT;

CARCINOMA, SQUAMOUS CELL; CAVEOLIN 1; HUMANS; MOUTH NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84922392127     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2482-z     Document Type: Review

References (82)

1. Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res. 2005;569:75–85.
2. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7:139–47.
3. De Jaeger K, Kavanagh MC, Hill RP. Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer. 2001;84:1280–5.
4. Patra SK. Dissecting lipid raft facilitated cell signalling pathways in cancer. Biochim Biophys Acta. 2008;1785(2):182–206.
5. Vallejo J, Hardin CD. Caveolin-1 functions as a scaffolding protein for phosphofructokinase in the metabolic organization of vascular smooth muscle. Biochemistry. 2004;43:16224–32.
6. Vallejo J, Hardin CD. Expression of caveolin-1 in lymphocytes induces caveolae formation and recruitment of phosphofructokinase to the plasma membrane. FASEB J. 2005;19:586–7.
7. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
8. Williams T, Lisanti M. The caveolin proteins. Genome Biol. 2004;5(3):214.
9. Palade GE. Fine structure of blood capillaries. J Appl Phys. 1953;24:1424.
10. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol. 1955;1:445–58.
11. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1(1):31–9.
12. Staubach S, Hanisch FG. Lipid rafts: signalling and sorting platforms of cells and their roles in cancer. Expert Rev Proteomics. 2011;8(2):263–77.
13. Razani B, Lisanti MP. Caveolins and caveolae: molecular and functional relationships. Exp Cell Res. 2001;271:36–44.
14. Li WP, Liu P, Pilcher BK, Anderson RG. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J Cell Sci. 2001;114:1397–408.
15. Uittenbogaard A, Ying Y, Smart EJ. Characterization of a cytosolic heat-shock protein–caveolin chaperone complex. Involvement in cholesterol trafficking. J Biol Chem. 1998;273:6525–32.
16. Liu P, Li WP, Machleidt T, Anderson RG. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat Cell Biol. 1999;1:369–75.
17. Hansen CG, Nichols BJ. Exploring the caves: cavins, caveolins and caveolae. Trends Cell Biol. 2010;20:177–86.
18. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449–52.
19. Aoki MN, Amarante MK, Oda JM, Watanabe MA. Caveolin involvement and modulation in breast cancer. Mini Rev Med Chem. 2011;11(13):1143–52.
20. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev. 2002;54(3):431–67.
21. Zhang Y, Iwabuchi K, Nunomura S, Hakomori S. Effect of synthetic sialyl 2-1 sphingosine and other glycosylsphingosines on the structure and function of the “glycosphingolipid signaling domain (GSD)” in mouse melanoma B16 cells. Biochemistry. 2000;39(10):2459–68.
22. Stan RV. Structure of caveolae. Biochim Biophys Acta. 2005;1746:334–48.
23. Frank PG, Cheung MW-C, Pavlides S, Llaverias G, Park DS, Lisanti MP. Caveolin-1 and regulation of cellular cholesterol homeostasis. Am J Physiol Heart Circ Physiol. 2006;291:677–86.
24. Frank PG, Pavlides S, Cheung MW-C, Daumer K, Lisanti MP. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol. 2008;295:242–8.
25. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol. 2005;288:494–506.
26. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423–67.
27. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP. Caveolin-1 expression is down regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry. 2000;39:13916–24.
28. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998;16:1391–7.
29. Razani B, Zhang XL, Bitzer M, von Gersdorff G, Bottinger EP, Lisanti MP. Caveolin-1 regulates transforming growth factor (TGF)beta/SMAD signalling through an interaction with the TGFbeta type I receptor. J Biol Chem. 2001;276:6727–38.
30. Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8(23):3984–4001.
31. Br E, Xiangbin X, Christoph R, et al. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res. 2007;67:8519–26.
32. Alshenawy HA, Ali MA. Differential caveolin-1 expression in colon carcinoma and its relation to E-cadherin-β-catenin complex. Ann Diagn Pathol. 2013;17(6):476–82.
33. Garcı’a AG, del Pozo MA. Caveolin-1 in cell polarization and directional migration. Eur J Cell Biol. 2008;87:641–7.
34. Glenney Jr JR. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem. 1989;264(34):20163–6.
35. Tekpli X, Holme JA, Sergent O, Lagadic-Gossmann D. Role for membrane remodelling in cell death: implication for health and disease. Toxicology. 2013;304(8):141–57.
36. Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003;4:499–515.
37. Liscovitch M, Burgermeister E, Jain N, Ravid D, Shatz M, Tencer L. Caveolin and cancer: a complex relationship. In: Mattson MP, editor. Membrane microdomain signaling lipid rafts in biology and medicine. Totowa: Humana Press; 2005. p. 161–90.
38. Li S, Okamoto T, Chun M, et al. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem. 1995;270:15693–701.
39. Lee H, Volonte D, Galbiati F, et al. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol. 2000;14:1750–75.
40. Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin-6-and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003;278:5794–801.
41. Schlege A, Arvan P, Lisanti MP. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. J Biol Chem. 2001;276:4398–408.
42. Fielding CJ, Bist A, Fielding PE. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci U S A. 1997;94:3753–8.
43. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008;27:715–35.
44. Cerezo A, Guadamillas MC, Goetz JG, et al. The absence of caveolin-1 increases proliferation and anchorage-independent growth by a Rac-dependent, Erkin dependent mechanism. Mol Cell Biol. 2009;29:5046–59.
45. Sun J, Gao J, Hu JB, et al. Expression of Cav-1 in tumour cells, rather than in stromal tissue, may promote cervical squamous cell carcinoma proliferation, and correlates with high-risk HPV infection. Oncol Rep. 2012;27(6):1733–40.
46. Miotti ESS, Mazzi M, De Santis G, Canevari S, Tomassetti A. Binding of nuclear caveolin-1 to promoter elements of growth-associated genes in ovarian carcinoma cells. Exp Cell Res. 2007;313:1307–17.
47. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 2009;8:2420–4.
48. Witkiewicz AK, Dasgupta A, Nguyen KH, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther. 2009;8:1167–75.
49. Witkiewicz AK, Dasgupta A, Sotgia F, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009;174:2023–34.
50. Ma X, Liu L, Nie W, et al. Prognostic role of caveolin in breast cancer: a meta analysis. Breast. 2013;22(4):462–9.
51. Kannan A, Krishnan A, Ali M, Subramaniam S, Halagowder D, Sivasithamparam ND. Caveolin-1 promotes gastric cancer progression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition. Eur J Cancer. 2014;50(1):204–15.
52. Taira J, Higashimoto Y. Caveolin-1 interacts with protein phosphatase 5 and modulates its activity in prostate cancer cells. Biochem Biophys Res Commun. 2013;431(4):724–8.
53. Felicetti F, Parolini I, Bottero L, et al. Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer. 2009;125(7):1514–22.
54. Steffens S, Schrader AJ, Blasig H, et al. Caveolin 1 protein expression in renal cell carcinoma predicts survival. BMC Urol. 2011;11:25.
55. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem. 1998;273:32380–3.
56. Sainz-Jaspeado M, Martin-Liberal J, Lagares-Tena L, Mateo-Lozano S, del GX M, Tirado OM. Caveolin-1 in sarcomas: friend or foe? Oncotarget. 2011;2(4):305–12.
57. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, et al. Understanding the “lethal” drivers of tumor-stroma co-evolution. Emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor microenvironment. Can Biol Ther. 2010;10(6):537–42.
58. Martinez-Outschoorn UE, Trimmer C, Lin Z, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival. Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle. 2010;9(17):3515–33.
59. Bakhshi FR, Shinin V, Mao M, et al. Role of oxidative stress-induced caveolin-1 S nitrosylation, ubiquitination, and degradation in endothelial cell dedifferentiation and idiopathic pulmonary arterial hypertension. Nitric Oxide. 2013;31(1):42.
60. Sanguinetti AR, Mastick CC. c-Abl is required for oxidative stress-induced phosphorylation of caveolin-1 on tyrosine 14. Cell Signal. 2003;15(3):289–98.
61. Rungtabnapa P, Nimmannit U, Halim H, Rojanasakul Y, Chanvorachote P. Hydrogen peroxide inhibits non-small cell lung cancer cell anoikis through the inhibition of caveolin-1 degradation. Am J Physiol Cell Physiol. 2011;300:235–45.
62. Hung KF, Lin SC, Liu CJ, Chang CS, Chang KW, Kao SY. The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J Oral Pathol Med. 2003;32(8):461–7.
63. Han SE, Park KH, Lee G, Huh YJ, Min BM. Mutation and aberrant expression of caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. Int J Oncol. 2004;24(2):435–40.
64. Xue J, Chen H, Diao L, Chen X, Xia D. Expression of caveolin-1 in tongue squamous cell carcinoma by quantum dots. Eur J Histochem. 2010;54(2):20.
65. Bau DT, Tsai MH, Tsou YA, et al. The association of caveolin-1 genotypes with oral cancer susceptibility in Taiwan. Ann Surg Oncol. 2011;18(5):1431–8.
66. Nakatani K, Wada T, Nakamura M, Uzawa K, Tanzawa H, Fujita S. Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(7):445–52.
67. Zhang H, Su L, Müller S, et al. Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. Br J Cancer. 2008;99(10):1684–94.
68. Masuelli L, Budillon A, Marzocchella L, et al. Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. J Cell Physiol. 2012;227(9):3344–53.
69. Masood R, Hochstim C, Cervenka B, et al. A novel orthotopic mouse model of head and neck cancer and lymph node metastasis. Oncogenesis. 2013;9:68.
70. Nohata N, Hanazawa T, Kikkawa N, et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol. 2011;38:209–17.
71. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A. 2003;100:8621–3.
72. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle. 2010;9(10):1960–71.
73. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NFkappaB. Cell Death Differ. 2006;13:759–72.
74. Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun. 2005;338:617–26.
75. Bellot G, Garcia-Medina R, Gounon P, et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 2009;29:2570–81.
76. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle. 2010;9:2423–33.
77. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107–20.
78. Wu H, Jiang H, Lu D, et al. Effect of simvastatin on glioma cell proliferation, migration, and apoptosis. Neurosurgery. 2009;65:1087–96.
79. Podar K, Tai YT, Cole CE, et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004;64:7500–6.
80. Sáinz-Jaspeado M, Lagares-Tena L, Lasheras J, et al. Caveolin-1 modulates the ability of Ewing’s sarcoma to metastasize. Mol Cancer Res. 2010;8:1489–500.
81. Gratton JP, Lin MI, Yu J, et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003;4:31–9.
82. Liscovitch M, Lavie Y. Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem Sci. 2000;25:530–4.